Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Cinacalcet on Gastric Acid Output in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy ambulatory men and postmenopausal women~* Age 45 to 70~* Avoid alcohol, antacids, H2 blockers, proton pump inhibitors, or antihistamines during the study.~Exclusion Criteria:~* Ionized Ca++ level \<4.39 mg/dl or \>5.02 mg/dl (normal reference range 4.18- 5.02).~* 24-hour UCa++ excretion \>350 mg.~* Cr \>1.3.~* AST/ALT values \>10% beyond reference range.~* Hgb level \<11.7 g/dl in women and \<13.2 g/dl in men.~* MCV level \>102 UM3.~* Basal acid output \>5 mEq/h in men and \>3.8 mEq/h in women.~* Basal acid output \<1 mEq/h in men and \<0.2 mEq/h in women.~* Age \<45 or \>70.~* Premenopausal or \<1 year post-menopause.~* Individuals following vegan diets.~* Current EtOH abuse.~* Lidocaine allergy. Medications~* Antacids~* H2 blockers~* Proton pump inhibitors~* Carafate~* Anticholinergic agents (i.e. TCA)~* Cholinergic agents~* Antihistamines in the last 3 weeks~* Cogentin~* Adrenergic blockers~* Thiazide diuretics~* Antiplatelet drugs~* Oral and Inhaled Glucocorticoids~* Bisphosphonates~* Raloxifene, Tamoxifen~* Tobacco~* EtOH during study~* rPTH~* Calcitonin~* Ketoconazole/Itraconazole~* Calcitriol~* Paricalcitol~* Drisdol, Ergocalciferol~* Phosphate binders~* Anticoagulant~* Erythromycin~* Hormone replacement therapy except vaginal estrogen creams~Exclusion Diseases~* Achlorhydria~* Pernicious anemia~* Zollinger Ellison syndrome~* Congestive heart failure~* Esophageal strictures or motility problems~* History of a GI bleed~* Prior upper GI surgery~* Malabsorption~* History of GI malignancy~* GERD, gastritis, duodenitis~* Active peptic ulcer disease~* Gallbladder disease~* Liver disease~* Pancreatitis~* Current kidney stone~* Renal disease~* Current hypoparathyroidism or hyperparathyroidism~* Moderate to Severe coronary artery disease~* Aortic aneurysm~* Seizure disorder~* Current Arrhythmia

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).